ARWR
ARWR
Positions held
Your positionsARWR isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | — | Enterprise value | — | Trailing P/E | — | Forward P/E | — |
| PEG | — | Price / book | — | Beta | — | Dividend yield | — |
| Revenue growth | — | Earnings growth | — | Gross margin | — | Operating margin | — |
| Profit margin | — | ROE | — | ROA | — | Debt / equity | — |
| Current ratio | — | Free cash flow | — | Analyst recommendation | — | Mean target | — |
| 52w high | — | 52w low | — |
Quarterly
No data yet.
Yearly (6y)
No data yet.
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-07 · Sector Update: Healthcare Stocks Flat to Higher Pre-Bell Wednesday
2026-10-07 · Arrowhead Says US FDA Includes Plozasiran in Split Real Time Application Review Pilot Program
2026-10-07 · Arrowhead Pharmaceuticals Granted Entry in the FDA STAR Pilot Program for Plozasiran in Severe Hypertriglyceridemia
2026-09-25 · RNAi drug specialist ADARx raises $446M IPO
2026-09-24 · ARWR Stock: Goldman Sachs Resumes Coverage With $74 Target As Clinical Catalysts Near
2026-09-19 · Arrowhead Pharmaceuticals (ARWR) On ARO DIMER PA Data And Whether Undervaluation Still Holds
2026-09-19 · Arrowhead Pharmaceuticals Spotlights Dual-Target RNAi Data, Plozasiran Launch Progress
2026-09-18 · Arrowhead Pharmaceuticals Eyes SHTG Filing as RNAi Pipeline Expands
2026-09-16 · Not A ‘Gangbusters Launch’ — Arrowhead Predicts Slow Burn to $3B-$4B Peak For Redemplo, Highlights ‘Massive Pipeline’
2026-09-16 · Arrowhead Achieves Clinical Validation for New Drug Platform
Price (daily)
Full chart · RSI · MACD · patterns